Characteristic | HIV Positive N = 102 | HIV Negative N = 25 | p-value1 |
---|---|---|---|
Age, years (mean, SD) | 34.2 (6.23) | 30.3 (3.99) | .004 |
Female, n (%) | 74 (72.6%) | 10 (40.0%) | .004 |
Education, years (mean, SD) | 9.1 (4.3) | 10.4 (4.2) | .207 |
CD4 cell count (mean, SD) | 130 (69.5) | N/A | .654 |
Plasma HIV RNA, log-10 copies/mL (mean, SD) | 4.9 (0.87) | N/A | .672 |
CES-D score (mean, SD) | 18.1 (11.4) | 9.1 (9.0) | < .001 |
Karnofsky Score | 84 (8.5) | 98 (4.1) | 0.001 |
Prevalence of depression symptoms | |||
   Baseline (HIV+ = 102 HIV- = 25) | 55 (53.9%) | 7 (28.0%) | .021 |
   3-month (HIV+ = 95 HIV- = 23) | 34 (36.0%) | 3 (13.0%) | .008 |
   6-month (HIV+ = 93 HIV- = 21) | 28 (30.0%) | 5 (24.0%) | .206 |
IHDS score (mean, SD) | 9.44 (1.8) | 11.10 (0.8) | < .001 |
Prevalence of cognitive impairment | |||
   Baseline -do- | 70 (68.6%) | 4 (16.0%) | < .0012 |
   3-month -do- | 34 (35.8%) | 5 (21.7%) |  |
   6-month -do- | 28 (30.1%) | 9 (42.8%) |  |
Dual prevalence of depression and cognitive impairment | |||
   Baseline -do- | 40 (39.2%) | 1 (4.0%) | .0132 |
   3-month -do- | 34 (35.8%) | 1 (4.0%) |  |
   6-month -do- | 28 (30.1%) | 2 (9.5%) |  |